{"id":495184,"date":"2024-01-25T04:30:18","date_gmt":"2024-01-25T09:30:18","guid":{"rendered":"https:\/\/platohealth.ai\/what-to-make-of-gileads-trodelvy-troubles-and-elevation-oncologys-surprising-rise\/"},"modified":"2024-01-25T04:44:46","modified_gmt":"2024-01-25T09:44:46","slug":"what-to-make-of-gileads-trodelvy-troubles-and-elevation-oncologys-surprising-rise","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/what-to-make-of-gileads-trodelvy-troubles-and-elevation-oncologys-surprising-rise\/","title":{"rendered":"What to make of Gilead\u2019s Trodelvy troubles and Elevation Oncology\u2019s surprising rise","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

H<\/span><\/span>ello! Some takes and thoughts on Gilead\u2019s Trodelvy troubles, Elevation Oncology\u2019s surprising rise, and Kura Oncology\u2019s \u201cwall-crossing\u201d stock sale.<\/p>\n

Gilead needs Arcellx more than ever<\/h2>\n

The clinical trial setback<\/a> for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company\u2019s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy \u2014 the type of cancer treatments where it truly excels?<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

If the answers to those questions are no and yes (I lean that way), then Gilead\u2019s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n